Pemafibrate Lowers Triglyceride Levels, but Doesn't Reduce CV Risks

(MedPage Today) -- While pemafibrate reduced triglycerides, very-low-density lipoprotein (VLDL) cholesterol, remnant cholesterol, and apolipoprotein C-III (ApoCIII) among adults with type 2 diabetes, it did not reduce rates of cardiovascular events...